Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63733657 in early Alzheimer's disease
jRCT2031200295Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of posidinemab in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in Integrated Alzheimer's Disease Rating Scale total score. Started May 2021; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031200295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200295.